Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT04119024. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Study identification
- NCT ID
- NCT04119024
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Anusha Kalbasi
- Other
- Enrollment
- 18 participants
Conditions and interventions
Conditions
- Acral Melanoma
- Adrenocortical Carcinoma
- Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Lung Adenocarcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Neuroendocrine Tumors
- Pancreatic Neuroendocrine Tumor
- Paraganglioma
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Pheochromocytoma
- Recurrent Malignant Solid Neoplasm
- Refractory Malignant Solid Neoplasm
- Thyroid Cancer
- Uveal Melanoma
Interventions
- Biopsy Procedure
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Cyclophosphamide Drug
- Fludarabine Phosphate Drug
- Fludeoxyglucose F-18 Other
- IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells Biological
- Magnetic Resonance Imaging Procedure
- Positron Emission Tomography Procedure
Procedure · Drug · Other + 1 more
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 6, 2025
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2026
- Last update posted
- Mar 16, 2026
2025 – 2026
United States locations
- U.S. sites
- 3
- U.S. states
- 1
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | Recruiting |
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | Recruiting |
| Stanford Cancer Institute | Stanford | California | 93405 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04119024, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2026 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04119024 live on ClinicalTrials.gov.